Literature DB >> 6724169

Decreased lysophospholipase and increased phospholipase A2 activity in ileal mucosa from patients with Crohn's disease.

T Bolin, R Heuman, R Sjödahl, C Tagesson.   

Abstract

Lysophospholipase (EC 3.1.1.5) and phospholipase A2 (EC 3.1.1.4) were determined in ileal mucosa from patients with Crohn's disease (CD) and non-inflammatory bowel diseases ( NIBD ). In addition, the activities of alkaline phosphatase, sucrase, maltase, and lactase were determined. The lysophospholipase activity, like that of alkaline phosphatase, sucrase and maltase, was decreased in affected areas of CD, whereas the phospholipase A2 activity was rather increased. Lysophospholipase and phospholipase A2 activities in apparently unaffected mucosa from CD patients were in between those in healthy mucosa from NIBD patients and those in affected mucosa from CD patients. These findings point to the possibility that the mucosal activity of lysophospholipase, like that of other brush border enzymes, is decreased in CD. This may render the mucosa less capable to handle lysolecithin, a potentially harmful agent formed in the intestine and known to induce inflammation in a number of experimental systems.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6724169     DOI: 10.1159/000199009

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  5 in total

Review 1.  Inflammatory intermediaries in inflammatory bowel disease.

Authors:  K Lauritsen; L S Laursen; K Bukhave; J Rask-Madsen
Journal:  Int J Colorectal Dis       Date:  1989       Impact factor: 2.571

2.  Lysophosphatidylcholine increases rat ileal permeability to macromolecules.

Authors:  C Tagesson; L Franzén; G Dahl; B Weström
Journal:  Gut       Date:  1985-04       Impact factor: 23.059

3.  Development of phospholipase A2 and lysophosphatidylcholine metabolising enzyme activities in the neonatal rat intestine.

Authors:  C Tagesson; E Telemo; G Ekström; B Weström
Journal:  Gut       Date:  1987-07       Impact factor: 23.059

4.  Inhibition of human colonic (Na+ + K+)-ATPase by arachidonic and linoleic acid.

Authors:  H Allgayer; L Brown; W Kruis; E Erdmann; G Paumgartner
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-04       Impact factor: 3.000

5.  Glucocorticoid treatment in ileal Crohn's disease: relief of symptoms but not of endoscopically viewed inflammation.

Authors:  G Olaison; R Sjödahl; C Tagesson
Journal:  Gut       Date:  1990-03       Impact factor: 23.059

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.